Introduction
Alprostadil was proposed for intracavernous injection-therapy by Adaikan and Ishii, 1986 in Prague at the Second World Meeting on Impotence.
1,2 The publications of its usefulness and safety in larger patient groups paved the way for a world-wide acceptance of Alprostadil in self-injection therapy. 3, 4 The high ef®cacy and low side-effect-rates with priapisms`1% and ®brotic alterations about 1% con®rmed in comprehensive retrospective literature reviews prompted the Clinical Guidelines Panel on Erectile Dysfunction of the American Urological Association to the statement that Alprostadil (PGE 1 ) monotherapy should be preferred to other vasoactive drugs in self-injection therapy. 5, 6 The convincing ef®cacy of Alprostadil with response-rates (complete rigid erections) of b 70% in large series is attributed to several pharmacological properties of the drug: stimulation of the adenylate cyclase with intracellular accumulation of cAMP and subsequent intracellular calcium decrease, direct stimulation of the maxi K (potassium)-channels resulting in hyperpolarization, inhibition of the noradrenaline release via presynaptic EP-receptors at the alpha 1 adrenoceptors, resulting in a decrease of sympathetic (adrenergic) tone, and suppression of Angiotensin II secretion. 7±10 Each of these different pharmacological effects contributes to cavernous smooth muscle relaxation.
Irrespective of the administered vasoactive drug, all published series with self-injection therapy of cavernous bodies reveal relatively high drop out rates up to 40±50% in long-term follow up. 5 This disadvantage of self-injection therapy is at least partly due to the necessity of needle-application as many patients exhibit needle-phobia. PadmaNathan et al, 1994 for the ®rst time introduced transurethral application of Alprostadil by means of MUSE TM (Medicated Urethral System for Erection).
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Due to the uncomplicated handling with a ready for use device and the needleless application MUSE TM enjoyed great popularity in a very short time and was registered in the USA in December 1996. Presently only one comprehensive publication on this subject is available with a follow-up of three months. 12 According to this publication, the investigated patients developed erections, which were considered suf®cient for sexual intercourse by several investigators in 65.9% (996 out of 1511) after transurethral Alprostadil up to 1000 mg. With the of®cial approval followed by a tremendous increase of its use in erectile dysfunction critical statements on the promised ef®cacy of MUSE TM could be heard which prompted us to compare ef®cacy and safety of transurethral (MUSE TM ) vs intracavernously injected Alprostadil in the diagnostic evaluation of male impotence.
Materials and methods
One hundred and three consecutive patients (51.7 y mean) with chronic erectile dysfunction ( b 6 months) underwent a complete diagnostic evaluation with patient's history, physical examination including penile palpation, determination of serum hormone-, (testosterone, prolactine) and glucose levels and pharmacotesting of cavernous bodies.
In all patients an intracavernous pharmacotesting with Alprostadil was performed up to dosages of 20 mg, in few cases up to 40 mg, respectively, and the results were compared with the outcome of transurethral application of Alprostadil with MUSE TM up to the highest dosage of 1000 mg. All investigations, including the drug administrations, were performed by the author himself. The start doses were 500 mg MUSE TM or 10 mg PGE 1 i.c., respectively, with a wash out interval of at least 48 h. In responders the dosages were lowered to 250 mg MUSE TM or 5 mg PGE 1 , and in non-responders increased to 1000 mg MUSE TM or 20 m PGE 1 , respectively. Both investigations were combined with a duplex-sonography of the penile arteries with determination of the systolic peak¯ow velocities as well as the enddiastolic¯ow in the deep penile arteries. The degree of erection was assessed according to an erection score of 1±5, as it was suggested in the MUSE TM studies.
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Patients with an erection score 5 (full rigid erection) and 4 (full tumescence, partial rigidity) were considered as responders. The start of the trial either with intracavernous or with transurethral Alprostadil (MUSE TM ) was by chance. After each investigation the patients were observed for at least 60 min in the of®ce with blood pressure monitoring in a sitting position and the registration of possible adverse events. At the end of the study each patient was asked upon his estimation which drug was more effective and/or better-tolerated and which drug he would prefer for home use. All patients were informed on the objective of the trial that is to ®nd out the best tolerable and most effective pharmacological treatment for the individual patient and all involved patients agreed to participate in the trial.
Results
Ef®cacy ( Table 1 and Table 2 . This table emphasizes the observations that in the majority of patients (77%) the high MUSE TM dosages of 500 mg (21%) or 1000 mg (56%) were necessary for achievement of the highest ED-score. After i.c. Alprostadil in most patients dosages of 10 mg (28%) and 20 mg (65%) had to be applied in order to reach the highest erection quality.
Patients' subjective assessments ( Table 3) After termination of the comparative trial 37.9% of the patents estimated i.c. Alprostadil superior and 15.5% inferior to MUSE TM . 46.6% of all patients indicated that they were not aware of great differences in terms of ef®cacy between the both methods with the majority of these patients falling under the non-responder category.
Duplex-sonography ®ndings ( Table 4 and 5) Systolic peak¯ow velocities: Whereas after MUSE TM -administration the systolic peak¯ow velocities in the dorsal arteries were 55.6 cm/s (left side) and 53.4 cm/s (right side) were somewhat higher than after i.c. Alprostadil (49.7 and 49.0 cm/s), the ratio was conversely in terms of the deep penile arteries with a slight advantage in favour of i.c. Alprostadil (Table 4 and 5). Concerning the recorded enddiastolic¯ow, which represents an indirect parameter for the degree of the completeness of cavernous smooth muscle relaxation, the measured values were twice as high after MUSE TM than after i.c. Alprostadil (Table 6 ). (Table 7) After i.c. Alprostadil 3.9% of the patients complained of severe penile pain and 6.7% of slight painful sensations during full rigid erections. On the other hand after MUSE TM -application in a total of 31% painful or burning sensations in the penis or urethra were encountered with additional 2.9% with severe testicle pain. Reddening of the varicose veins of the lower limbs with simultaneous painful sensations occurred in 2.9%. Temporary urethral bleeding after MUSE TM -application was observed in 4.8% (5 out of 103) and repeatedly occurred in four of these ®ve patients after further administration during the titration phase. Adverse events of general health conditions attributable to a blood pressure decay, beginning 8±15 min after application and lasting for about 10 min were observed in seven (6.8%) patients with one patient suffering from a short-term syncope. The relatively high percentage of patients with needle-phobia of any degree prompted several researchers to pursue application modalities of vasoactive drugs different from intracavernous injection-therapy. So, for example studies with intraurethral Prostaglandin E 2 -applications were published by Wolfson et al, 13 Schmidt et al, 14 Rozas et al, 15 Florante et al 16 with response-rates of up to 76%. A ®rst comprehensive overview on the ef®cacy and safety of transurethral Alprostadil with MU-SE TM was published by Padma Nathan et al.
Side-Effects

Discussion
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According to this paper 65.9% (996 out of 1511) of the patients had erections being considered suf®-cient for intercourse (erection score 4 and 5) during in-clinic-testing'. With respect to these reported ef®cacy-rates it must be realized, that in 25.4% (384 out of 1511) of all patients the erectile dysfunction was due to a condition after radical prostatectomy, therefore this patient population showed a patientselection-bias. This is in so far of importance, as patients with an underlying neurologic etiology of their erectile disturbances (damage of cavernous nerves) are more likely to respond to Alprostadil, as it was also proven in this trial with ef®cacy-rates of 76.7% in the radical-prostatectomy-group compared to 65.9% in all patients. 12, 17 Although only responders of the`in-clinic-titration-phase' were enrolled in a three months placebo controlled home treatment trial the success-rates after MUSE TM -application were only 50.4% (2485 out of 4933) compared to 10.4% after placebo. Similar ef®cacy-rates were yielded in the Multi-Center-European MUSE TM trial. 18 In the presented cross-over study the total response-rate in unselected patients with erectile dysfunction amounted to 43% after MUSE TM compared to 70% after intracavernous Alprostadil. A subdivision of the responders (ED-score 4 and 5) showed, that only 10% (10 out of 103) of the patients had full rigid erections after MUSE TM , compared to 48% (49 out of 103) after i.c. Alprostadil. The majority of the MUSE TM -responders had incomplete erections with full tumescence and partial rigidity. These observations are re¯ected by the duplexsonographic blood¯ow measurements. Whereas the systolic peak-¯ow velocities of both, the dorsal arteries and the deep penile arteries revealed only insigni®cant differences between MUSE TM and i.c. Alprostadil, the average enddiastolic blood¯ow values of the deep penile arteries ranged between 4.5 and 4.8 cm/s after i.c. Alprostadil and were twice as high after MUSE TM with 9.2±9.4 cm/s. There is general agreement in the literature, that enddiastolic-¯ow values above 3±5 cm/s are indicative for insuf®cient cavernous smooth muscle-relaxation.
19±24
Both the assessments of the erectile response by the investigator, as well as the values of the enddiastolic blood¯ow in the deep penile arteries provided proof that in the majority of patients the erections, provoked by MUSE TM , are incomplete and require additionally suf®cient sexual stimulation. This essential shortcoming of nonachievement of full rigidity is re¯ected by the fact, that only 50% of all MUSE TM -applications at home resulted in successful intercourse compared to success-rates of 87±94% after i.c. Alprostadil, which have been documented in the large prospective selfinjection trials of the companies Schwarz Pharma, Germany (Viridal TM /Edex TM ) and Pharmacia & Upjohn, USA (Caverject  TM ) . 12 ,25±28 Therefore in regard to ef®cacy and reliability i.c. Alprostadil is considerably superior to MUSE TM , both in the titrationphase and in home-use.
Concerning the side-effects of MUSE TM in the reported series of Padma-Nathan and the own present series the occurrence of penile/urethral pain ranked about 32% and is thus considerably higher than the reported 10±12% after intracavernous injection of Alprostadil. 5, 12 A further important complication after MUSE TM -administration is the provocation of urethral lacerations with temporary bleeding out of the external urethral ori®ce in 5%. 12 Although Spivack et al 29 assure that these 5% of minor' urethral trauma resolved spontaneously without any sequelae for the urethra, it must be argued, that no appropriate investigations like urethroscopy or urethrography were conducted in the long-term follow-up of these patients with urethral trauma after MUSE TM -application. Keeping in mind the fact, that principally each minor urethral trauma may induce an urethral stricture, the statement that in long-term observations after MUSE TM -application such urethral strictures will not occur, even in cases with repeated urethral bleeding, remains an unproven speculation. Especially after the higher MUSE TM dosages of 500± 1000 mg systemic adverse events attributable to a blood pressure decay were encountered in 2±8% with syncopes in 0.4±1%. 12, 29, 30 Therefore it seems very important and is also recommended in the package insert of MUSE TM that the ®rst MUSE TMapplication, especially the high dosages has to be performed in the physician's of®ce with bloodpressure monitoring. The frequently encountered 28,32,33 These important positive inuences on patients and the partnership render both methods indispensable in the therapeutic management of male impotence. The needleless administration with a very user-friendly application device prompt many patients to prefer MUSE TM to selfinjection therapy and those patients in whom MUSE TM works reliably at home are very satis®ed with this new therapeutic option. On the other hand the considerably lower ef®cacy of MUSE TM compared to i.c. Alprostadil exclude the majority of impotent patients from MUSE TM -therapy in whom self-injection therapy will however be effective. In addition whereas the drug-safety is ®nally assessed for self-injection therapy, this is not true for MUSE TM especially with regard to penile ®brosis and the possibility of urethral strictures. Regarding ef®cacy and reliability of both methods, self-injection therapy with Alprostadil will remain the`Gold Standard' in the pharmacological treatment of erectile dysfunction, while MUSE TM will be reserved for a subset of these patients. 
